Sign In
Buy VERX
$12.98
+0.600 (+4.85%)
At Close: Jul 13, 2026
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex's cystic fibrosis (CF) medic
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health
Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch
03:09pm, Wednesday, 09'th Jul 2025
Vertex Pharmaceuticals Incorporated remains a Buy: its cystic fibrosis franchise ensures robust revenue for a decade, and its pipeline offers multiple long-term growth drivers. Casgevy's long-term dat
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
04:00pm, Tuesday, 08'th Jul 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The compa
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
09:35am, Wednesday, 02'nd Jul 2025
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
Vertex's next-generation cystic fibrosis drug gets EU approval
07:46am, Tuesday, 01'st Jul 2025
Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis.
Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
07:34am, Tuesday, 01'st Jul 2025
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?
09:31am, Monday, 30'th Jun 2025
VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold.
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
04:00am, Monday, 23'rd Jun 2025
BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agre
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
07:15pm, Friday, 20'th Jun 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORW
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with
Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
08:14am, Monday, 02'nd Jun 2025
Both Vertex and Eli Lilly are entering the non-opioid pain management market, targeting the promising $20B+ opportunity. Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pai
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
09:46am, Friday, 23'rd May 2025
Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Ver
HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court, Southern District of Texas, Houston Division has approved the following announcement
Vertex to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 15'th May 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor
